침습성 프로락틴 분비 뇌하수체 선종에서 Bromocriptine의 치료효과 = The Effect of Bromocriptine Treatment for Invasive Prolactinoma

다국어 초록 (Multilingual Abstract)

Objective: The prolactinoma is the most common pituitary tumor and sometimes shows severe invasiveness to the adjacent cavernous sinus, especially in the male patient. The dopamine agonist can be used as an alternative treatment modality to surgery. But, the transsphenoidal or transcranial approach for tumor removal has been more preferred treatment option of neurosurgeons in invasive prolactinoma. Especially rapid decompression of mass effect and resolution of the neurologic deficit is demanded. The prospective study is done in order to identify the therapeutic efficacy of bromocriptine as an initial treatment option for the invasive prolactionomas. Methods: Twenty patients with invasive prolactinoma were studied. Preoperative neurological and endocrinological evaluations were done, and size and invasiveness of the tumor was estimated on MRI. Bromocriptine was administrated by increasing dose planning reaching maximum dose at 1 month of treatment, with close neurological and endocrinological monitoring. At 3months after treatment, MRI was taken and decision was made whether to continue bromocriptine or to have surgical intervention. Results: Thirteen patients showed excellent result with only bromocriptine treatment. These patients showed not only marked reduction of tumor volume and prolactin level, but also, improving clinical symptoms and other hormonal deficits. 13patients who had visual field defect and decreased visual acuity had all improved visual symptoms. But, the remaining 4patients required surgical treatment due to insufficient reduction of tumor size inspite of normalized prolactin level within 3months. Remaining 2patients had $20{\sim}30%$ of tumor size reduction, but prolactin level was not normalized. One patient required radiation therapy. Conclusion: Bromociptine can be used as initial treatment for the invasive prolactinomas with careful monitoring of the neurological and endocrinological status. It should be carefully followed up for tumor size reduction within 3 months after initiation of treatment.

참고문헌 (Reference)

1 Tyrrell JB, "Transsphenoidal microsurgical therapy of prolactinomas:initial outcomes and long-term results" 44 : 254-257, 1999

2 Tindall GT, "Transsphenoidal microsurgery for pituitary tumors associated with hyperprolactinemia" 48 : 849-860, 1978

3 Lee KH, "Transcavernous Approach for invasivepituitary adenoma" 35 : 53-59, 2004

4 Jeon WY, "The Surgical Result of Pituitary Adenoma by Trassphenoidal Approach" 30 : 1278-1283, 2001

5 Naokatsu S, "Surgical indication after bromocriptine therapy on giant prolactinoma:Effects and limitation of the medical treatment" 45 : 529-537, 1998

6 Jung TY, "Surgical Outcome of Pituitary Prolactinomas" 32 : 307-311, 2002

7 Franks S, "Studies of prolactin in pituitary disease" 67 : 55-, 1975

8 Serri O, "Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma.N Eng" 309 : 280-283, 1983

9 Hubbard JL, "Prolactinsecreting adenomas.The preoperative response to bromocriptine treatment and surgical outcome" 67 : 816-821, 1987

10 Kwon TH, "Prolactinoma:Surgical Treatment and Outcome" 27 : 357-362, 1998

11 Schlechte J, "Prolactin-secreting pituitary tumors in amenorrheic women:a comprehensive study" 1 : 295-308, 1980

12 Joseph JP, "Primary medical therapy of micro-and macroprolactinomas in Men" 85 : 3053-3057, 2000

13 Landolt AM, "Pituitary adenomas" Churchill Livingstone pituitary ade (pituitary ade): 1992

14 Barrow DL, "Management of prolactinomaassociated with Very high serum prolactin levels" 68 : 554-558, 1988

15 Schcart WA, "Implication of very high prolactin levels associated with pituitary tumors" 52 : 226-228, 1980

16 Raj KS, "Giant prolactinomas:clinical management and long-term follow up" 97 : 299-3063, 2002

17 Iwai Y, "Giant basal prolactinoma extending into the nasal cavity" 37 : 280-283, 1992

18 Nelson PB, "Factors in predicting outcome from operation in patients with prolactin secreting pituitary adenomas" 13 : 634-641, 1983

19 Enrica C, "Diagnosis and drug therapy of prolactinoma" 51 : 954-963, 1996

20 Mark EM, "Bromocriptine as Primary Therapy for Prolactin-Secreting macroadenomas,Results of a Prospective Multicenter study" 60 : 698-705, 1985

21 Acquati S, "A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma" 45 : 65-69, 2001